Medpace (MEDP) Financial Analysis & Valuation | Quarter Chart
Medpace (MEDP)
MEDPPrice: $534.72
Fair Value: 🔒
🔒score
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical... more
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services... more
Description
Shares
| Market Cap | $15.27B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Diagnostics & Research |
| Country | US | CEO | August James Troendle |
| IPO Date | 2016-08-11 | CAGR | 0.2% |
| Employees | 5,900 | Website | www.medpace.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 2.87% | Total Yield | 2.87% |
MEDP chart loading...
Fundamentals
Technicals
| Enterprise Value | $16.17B | P/E Ratio | 33.61 |
| Forward P/E | 28.5 | PEG Ratio | 2.03 |
| P/S Ratio | 7.1 | P/B Ratio | 31.6 |
| P/CF Ratio | 25.57 | P/FCF Ratio | 25.73 |
| EPS | $15.91 | EPS Growth 1Y | 21.53% |
| EPS Growth 3Y | 101.77% | EPS Growth 5Y | 278.15% |
| Revenue Growth 1Y | 24.19% | Gross Margin | 0.29% |
| Operating Margin | 0.21% | Profit Margin | 0.17% |
| ROE | 1.21% | ROA | 0.22% |
| ROCE | 0.72% | Current Ratio | 0.85 |
| Quick Ratio | 0.85 | Cash Ratio | 0.49 |
| Debt/Equity | 0.24 | Interest Coverage | — |
| Altman Z Score | 7.82 | Piotroski Score | 7 |